Last reviewed · How we verify
hemodynamics-based individualized antihypertensive therapy
This is a personalized treatment approach that tailors antihypertensive drug selection based on individual hemodynamic profiles rather than a single drug entity.
This is a personalized treatment approach that tailors antihypertensive drug selection based on individual hemodynamic profiles rather than a single drug entity. Used for Hypertension management with personalized hemodynamic profiling.
At a glance
| Generic name | hemodynamics-based individualized antihypertensive therapy |
|---|---|
| Also known as | individualized therapy |
| Sponsor | The Third Xiangya Hospital of Central South University |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Hemodynamics-based individualized antihypertensive therapy is a clinical strategy that uses hemodynamic assessment (such as cardiac output, systemic vascular resistance, and blood pressure patterns) to guide the selection and optimization of antihypertensive medications for individual patients. Rather than a specific pharmaceutical agent, it represents a therapeutic approach where different classes of antihypertensives (ACE inhibitors, beta-blockers, calcium channel blockers, diuretics, etc.) are chosen based on each patient's unique hemodynamic profile to achieve better blood pressure control and clinical outcomes.
Approved indications
- Hypertension management with personalized hemodynamic profiling
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: